Suppr超能文献

[心脏再同步治疗的适应证:2005年共识]

[Indication for cardiac resynchronization therapy: Consensus 2005].

作者信息

Israel C W, Butter C

机构信息

J.-W.-Goethe-Universitätsklinik, Medizinische Klinik III-Kardiologie, Theodor-Stern-Kai 7, 60590 Frankfurt.

出版信息

Herzschrittmacherther Elektrophysiol. 2006;17 Suppl 1:I80-6. doi: 10.1007/s00399-006-1112-x.

Abstract

The indication for cardiac resynchronization therapy (CRT) using biventricular pacing or ICD systems has to be highly differentiated to optimize the proportion of patients who derive significant symptomatic benefit from this therapy, on the one hand, and to avoid this invasive treatment in patients with a low probability of clinical success of CRT, on the other hand. As a consensus in 2005, it can be put forward that there is sufficient evidence for an indication for CRT from clinical studies for the following characteristics: 1) Heart failure in NYHA functional class III or IV (if cardiac recompensation to class III is at least temporarily successful), 2) left ventricular ejection fraction < or =35%, 3) QRS duration >130 ms, particularly if left bundle branch block is present, 4) sinus rhythm. In addition, available data also suggest an indication for CRT in patients with atrial fibrillation if the other criteria listed above are met. The indication for CRT is unclear in patients with other intraventricular conduction delay (particularly right bundle branch block) while patients with left bundle branch block and a QRS duration of 120-130 ms seem to benefit if echocardiographic criteria demonstrate ventricular dyssynchrony. Since a multiplicity of echocardiographic criteria of ventricular dyssynchrony exists which is neither standardized nor evaluated in large-scale randomized trials, ventricular dyssynchrony on echocardiography alone cannot be regarded as an established indication for CRT without a QRS complex > or =120 ms. Similarly, whether heart failure in functional state NYHA II should be regarded as a CRT indication is currently being investigated in the randomized RAFT and MADIT-CRT trials.

摘要

对于使用双心室起搏或植入式心脏除颤器(ICD)系统的心脏再同步治疗(CRT),其适应证必须进行高度区分,一方面是为了优化能从该治疗中获得显著症状改善的患者比例,另一方面是为了避免在CRT临床成功可能性较低的患者中进行这种侵入性治疗。作为2005年的一项共识,可以提出临床研究有充分证据支持以下特征作为CRT的适应证:1)纽约心脏协会(NYHA)心功能分级为III级或IV级的心力衰竭(如果心脏代偿至III级至少暂时成功),2)左心室射血分数≤35%,3)QRS波时限>130毫秒,特别是存在左束支传导阻滞时,4)窦性心律。此外,现有数据还表明,如果满足上述列出的其他标准,房颤患者也有CRT适应证。对于其他室内传导延迟(特别是右束支传导阻滞)的患者,CRT的适应证尚不明确,而对于左束支传导阻滞且QRS波时限为120 - 130毫秒的患者,如果超声心动图标准显示心室不同步,似乎会从中获益。由于存在多种心室不同步的超声心动图标准,且这些标准既未标准化,也未在大规模随机试验中进行评估,因此仅靠超声心动图显示的心室不同步,在QRS波时限<120毫秒时不能被视为CRT的确立适应证。同样,NYHA II级功能状态的心力衰竭是否应被视为CRT适应证,目前正在RAFT和MADIT - CRT随机试验中进行研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验